Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, ...
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation ...
Initial blood work found hints of an infection, and the doctors initially suspected a bacterial skin infection (cellulitis) ...
After assessing data from the first 46 adults with refractory nontuberculous mycobacterial lung disease who completed the ...
Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 9:00 ...
NTM lung disease is a rare condition affecting approximately 100,000 people in the U.S. and 150,000 in Japan, with about 15-20% of patients considered refractory to standard treatments. The disease is ...
If you are also suffering from a bacterial infection and have waited long enough for its natural recovery you may need a Swab ...
The Global TB Report 2025 released by the World Health Organization (WHO) highlights that India’s TB incidence has reduced ...
Over the last few decades, the development of nasal vaccines has been used to deliver treatment for various diseases, ...
14don MSN
How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace
Bacteria can serve as couriers for these anti-cancer vaccines. Using genetic engineering, the genetic instructions (or DNA) in bacteria that might make us unwell can be removed and replaced with DNA ...
Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM ESTCompany ParticipantsWilliam Lewis - President, CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback